- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01683292
Single-Centre Study of VR040(Inhaled Apomorphine) in Idiopathic Parkinson's Disease
September 7, 2012 updated by: Dr Donald Grosset, South Glasgow University Hospitals NHS Trust
An Ascending-Dose, Single-Centre Study Investigating the Safety, Tolerability, Efficacy, and Pharmacokinetics of VR040(Inhaled Apomorphine)in Parkinson's Disease
In this first study of inhaled apomorphine in Parkinson's disease patients, the primary objective is to find the minimum efficacious dose of apomorphine that is useful in rescuing patients during 'off' periods.
Safety, tolerability and pharmacokinetics of inhaled apomorphine will be assessed during the study.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Objectives:
Study Type
Interventional
Enrollment (Actual)
29
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Glasgow, United Kingdom, G51 4TF
- Southern General Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
30 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients with established idiopathic PD (via fulfilment of Steps 1 and 2 of the UK Brain Bank Criteria), of at least 3 years duration prior to study entry, who were on specific and optimised anti-Parkinson medication (levodopa and/or dopamine agonists), and with motor fluctuations.
- Patients with a modified Hoehn and Yahr disease severity scoring of between 2 and 4 in an "on" state.
- Men or women aged over 30 years.
- Patients with a signed and dated written valid consent obtained prior to participation.
- Female patients must have been of non-childbearing potential (ie, physiologically incapable of becoming pregnant, including any female who was post-menopausal) or of child-bearing potential with a negative pregnancy test (urine or serum) at screening.
- Patients who experienced motor fluctuations with recognisable "off" periods in control of motor symptoms, as assessed by the motor fluctuation questionnaire (patients were to have reported at least 1 "Yes" response to the questions in the motor fluctuation questionnaire).
- Patient willing and able to comply with study procedures.-
Exclusion Criteria:
- Patients who had participated in a trial with an investigational product within 3 months prior to randomisation at Visit 2.
- Patients with serious uncontrolled disease including serious psychological disorders likely to interfere with the study and/or likely to cause death within 6 months of the study completion.
- Patients with previous intolerance to apomorphine.
- Patients with a previous significant complication from oral dopamine agonist therapy including hospitalisation following dopamine agonist introduction and/or the development of hallucinations or other adverse neuropsychiatric features following introduction of sc apomorphine.
- Women lactating, pregnant, or of child-bearing potential not using a reliable contraceptive method.
- Patients with known HIV or active chronic hepatitis B or C infection.
- Patients with any clinically significant abnormality following review of screening laboratory data and full physical examination.
- Patients who, in the Investigator's opinion, were unsuitable for the study for any reason.
- Patients with clinically significant blood test abnormalities and previous medical history/intercurrent illnesses that may have compromised the safety of the patient in the study.
- Patients with major ECG abnormalities (as judged by the Investigator).
- Patients with a FEV1 <65%.
- Patients showing a postural decrease in systolic blood pressure (BP) of > 20 mm Hg, or showing significant clinical symptoms associated with orthostatic hypotension.
- Patients with persistent elevation of BP, with average systolic readings of 160 mm Hg or average diastolic readings of 100 mm Hg.
- Patients taking anabolic steroids, traditional antipsychotics (unless low dose), and antiemetics other than domperidone.
- Patients taking agents of the 5HT3 antagonist class including ondansetron, granisetron, dolasetron, palonosetron, and alosetron.
- Patients with existing cancer and those in remission for less than 5 years.
- Patients with evidence (as ascertained from examination, tests or history) to indicate cardiovascular, gastrointestinal tract, liver, kidney, central nervous system, pulmonary system, or bone marrow disorders that in the Investigator's opinion compromised patient safety.
- Patients who were known non-responders to apomorphine treatment for "off" episodes.
- Patients with a history of drug or alcohol abuse in the 12 months prior to entry.
- Patients with a history of clinically significant allergies to VR040 formulation constituents (including lactose and opioids) and domperidone.
- Patients with signs or symptoms suggestive of schizophrenia, dementia, "Parkinson plus" syndromes, or unstable systemic disease
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Inhaled VR040
Inhaled apomorphine, dry powder, VR040 at fine particle doses (FPD) of 0.2mg, 0.5mg and 0.8mg.
A single dose, followed by a second dose at 12 minutes if efficacy end point was not attained.
|
Other Names:
|
Placebo Comparator: Placebo
Inhaled dry powder.
A single dose, followed by a second dose at 12 minutes if efficacy end point was not attained.
|
Placebo arm
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The proportion of patients "on" at any time post-dosing.
Time Frame: up to 80 minutes
|
Parkinson's motor severity assessed by a clinician, and disease state assessment by the patient, were performed at baseline during an 'off' state, and at specified times after test drug administration.
|
up to 80 minutes
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Duration that patients remain in an "on" state.
Time Frame: until return to "off" up to 3 hours
|
Time from when patient switched "on" after inhalation of study product, until patient returned to "off" state.
|
until return to "off" up to 3 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2006
Primary Completion (Actual)
June 1, 2006
Study Completion (Actual)
May 1, 2007
Study Registration Dates
First Submitted
September 7, 2012
First Submitted That Met QC Criteria
September 7, 2012
First Posted (Estimate)
September 11, 2012
Study Record Updates
Last Update Posted (Estimate)
September 11, 2012
Last Update Submitted That Met QC Criteria
September 7, 2012
Last Verified
September 1, 2012
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Parkinsonian Disorders
- Basal Ganglia Diseases
- Movement Disorders
- Synucleinopathies
- Neurodegenerative Diseases
- Parkinson Disease
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Gastrointestinal Agents
- Dopamine Agonists
- Dopamine Agents
- Emetics
- Apomorphine
Other Study ID Numbers
- VR040/001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson's Disease
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
Assistance Publique - Hôpitaux de ParisFrance Parkinson AssociationUnknownHealthy Controls | Parkinson's Disease With LRRK2 Mutation | Parkinson's Disease Without LRRK2 MutationFrance
-
Merck Sharp & Dohme LLCCompletedParkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
-
Universidade Federal de PernambucoCompletedParkinson's Disease.Brazil
-
University Hospital, GrenobleCompletedParkinson's Disease (Disorder)France
-
Neurocrine BiosciencesVoyager TherapeuticsCompletedBrain Diseases | Central Nervous System Diseases | Nervous System Diseases | Parkinson's Disease | Parkinsonian Disorders | Movement Disorders | Neurodegenerative Diseases | Idiopathic Parkinson's Disease | Basal Ganglia DiseaseUnited States
-
Shanghai East HospitalShanghai iCELL Biotechnology Co., Ltd, Shanghai, ChinaRecruitingIdiopathic Parkinson's DiseaseChina
-
Beijing Tiantan HospitalRecruitingPD - Parkinson's DiseaseChina
-
AbbVieActive, not recruitingParkinson's Disease (PD)United States, Australia
-
AbbVieCompletedParkinson's Disease (PD)United States, Australia
Clinical Trials on Inhaled VR040
-
South Glasgow University Hospitals NHS TrustVectura LimitedCompletedParkinson's DiseaseUnited Kingdom, Serbia
-
Synspira, Inc.TerminatedLung Diseases | Cystic Fibrosis | Pulmonary Disease | Antibiotic Resistant Infection | Respiratory Tract Disease | Cystic Fibrosis Pulmonary Exacerbation | Lung Inflammation | Burkholderia Infections | Lung Infection | Multi-antibiotic Resistance | Pulmonary Inflammation | Lung Infection Pseudomonal | Cystic Fibrosis... and other conditionsUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveCzechia, Hungary
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveHungary, Slovakia
-
Galecto Biotech ABCompletedIdiopathic Pulmonary FibrosisUnited Kingdom
-
GlaxoSmithKlineCompletedCoughUnited Kingdom
-
Boehringer IngelheimCompletedPulmonary Disease, Chronic ObstructiveSpain
-
Pearl Therapeutics, Inc.Completed
-
Liquidia Technologies, Inc.Nuventra, Inc.CompletedPrimary Pulmonary HypertensionUnited States
-
Liquidia Technologies, Inc.Nuventra, Inc.Active, not recruitingPrimary Pulmonary HypertensionUnited States